These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 2409240)

  • 1. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma.
    Eisenberger MA; Simon R; O'Dwyer PJ; Wittes RE; Friedman MA
    J Clin Oncol; 1985 Jun; 3(6):827-41. PubMed ID: 2409240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chemotherapy of prostatic carcinoma].
    Wirth M; Altwein JE
    Urologe A; 1991 Jan; 30(1):17-24. PubMed ID: 2014582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy for prostate carcinoma.
    Eisenberger MA
    NCI Monogr; 1988; (7):151-63. PubMed ID: 3050534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?
    Tannock IF
    J Clin Oncol; 1985 Jul; 3(7):1013-21. PubMed ID: 3894584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy of hormonally unresponsive prostatic carcinoma.
    deKernion JB; Lindner A
    Urol Clin North Am; 1984 May; 11(2):319-26. PubMed ID: 6233779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Advanced prostate cancer--a therapeutic dilemma?].
    Rübben H; Altwein JE
    Urologe A; 1987 Jan; 26(1):7-14. PubMed ID: 3576864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a Southwest Oncology Group Study.
    Kies MS; Mira JG; Crowley JJ; Chen TT; Pazdur R; Grozea PN; Rivkin SE; Coltman CA; Ward JH; Livingston RB
    J Clin Oncol; 1987 Apr; 5(4):592-600. PubMed ID: 3031226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A critical assessment of the role of chemotherapy for endocrine-resistant prostatic carcinoma.
    Eisenberger MA; Bezerdjian L; Kalash S
    Urol Clin North Am; 1987 Nov; 14(4):695-706. PubMed ID: 3314063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A trial of combination chemotherapy followed by hormonal therapy for previously untreated metastatic carcinoma of the prostate.
    Seifter EJ; Bunn PA; Cohen MH; Makuch RW; Dunnick NR; Javadpour N; Bensimon H; Eddy JL; Minna JD; Ihde DC
    J Clin Oncol; 1986 Sep; 4(9):1365-73. PubMed ID: 2943877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. National randomized study of chemotherapeutic agents in advanced prostatic carcinoma: a progress report.
    Johnson DE; Scott WW; Gibbons RP; Prout GR; Schmidt JD; Chu TM; Gaeta J; Saroff J; Murphy GP
    Cancer Treat Rep; 1977; 61(2):317-23. PubMed ID: 141326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer. Chemotherapy.
    Gibbons RP
    Cancer; 1987 Aug; 60(3 Suppl):586-8. PubMed ID: 3297287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study.
    Osborne CK; Blumenstein B; Crawford ED; Coltman CA; Smith AY; Lambuth BW; Chapman RA
    J Clin Oncol; 1990 Oct; 8(10):1675-82. PubMed ID: 2213104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [What is the objective of second-line chemotherapy after failure of first-line chemotherapy in hormone-resistant metastatic prostate?].
    El Demery M; Pouessel D; Avancès C; Iborra F; Rebillard X; Faix A; Ségui B; Delbos O; Ayuso D; Culine S
    Prog Urol; 2006 Jun; 16(3):320-3. PubMed ID: 16821344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.
    Sava T; Basso U; Porcaro A; Cetto GL
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):53-62. PubMed ID: 15757438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment for hormone-refractory or relapsing prostatic cancer].
    Hirao Y; Ozono S; Okajima E
    Gan To Kagaku Ryoho; 1996 Mar; 23(4):418-26. PubMed ID: 8678492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chemotherapy in prostatic carcinoma].
    Pérez Manga G; Arranz Arija JA; García Gómez R; Salinas Hernández P; González del Val R
    Arch Esp Urol; 1993 Mar; 46(2):116-26. PubMed ID: 8498851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma.
    Page JP; Levi JA; Woods RL; Tattersall MN; Fox RM; Coates AS
    Cancer Treat Rep; 1985 Jan; 69(1):105-7. PubMed ID: 3881176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data.
    Fizazi K; Le Maitre A; Hudes G; Berry WR; Kelly WK; Eymard JC; Logothetis CJ; Pignon JP; Michiels S;
    Lancet Oncol; 2007 Nov; 8(11):994-1000. PubMed ID: 17942366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.